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Abstract
Background: Paget's disease of bone (PDB) disrupts normal bone architecture and causes pain,
deformity, deafness, osteoarthritis, and fractures. Genetic factors play a role in PDB and genetic
tests are now conducted for research purposes. It is thus timely to investigate the potential for a
clinical programme of genetic testing and preventative treatment for people who have a family
history of PDB. This study examines the beliefs of relatives of people with PDB. It focuses
particularly on illness and treatment representations as predictors of the acceptability and uptake
of potential clinical programmes. Illness representations are examined using Leventhal's Common
Sense Self-Regulation Model while cognitions about treatment behaviours (acceptance of testing
and treatment uptake) are conceptualised within the Theory of Planned Behaviour.
Methods/Design: A postal questionnaire of non-affected relatives of people with Paget's disease.
The sample will include relatives of Paget's patients with a family history of Paget's disease and
relatives of Paget's patients without a family history of Paget's disease. The questionnaire will explore
whether a range of factors relate to acceptability of a programme of genetic testing and preventive
treatment in relatives of Paget's disease sufferers. The questionnaire will include several measures:
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BMC Health Services Research 2008, 8:116 http://www.biomedcentral.com/1472-6963/8/116illness representations (as measured by the Brief Illness Perceptions Questionnaire); treatment
representations (as measured by Theory of Planned Behaviour-based question items, informed by
a prior interview elicitation study); descriptive and demographic details; and questions exploring
family environment and beliefs of other important people.
Data will also be collected from family members who have been diagnosed with Paget's disease to
describe the disease presentation and its distribution within a family.
Discussion: The answers to these measures will inform the feasibility of a programme of genetic
testing and preventive treatment for individuals who are at a high risk of developing Paget's disease
because they carry an appropriate genetic mutation. They will also contribute to theoretical and
empirical approaches to predicting diagnostic and treatment behaviours from the combined
theoretical models.
Background
The need for this research
Over recent years, advances in human molecular genetics
have resulted in the identification of polymorphisms and
mutations in several genes that cause or predispose to dis-
eases such as cancer, neurodegenerative conditions and
inborn errors of metabolism. For some of these condi-
tions, such as Huntington's disease and Muscular Dystro-
phy, it is possible to offer a genetic test that will give
information on the probability of the disease occurring.
For other diseases, such as hypercholesterolaemia and
haemochromatosis, identification of genetic susceptibil-
ity can be used as a risk factor to inform management
strategies and treatment decisions in a similar way to
other clinical risk factors.
The process of exploring the feasibility of new biomedical
developments includes the likely uptake of new tests and
treatments.
For example, offering a test to inform on the probability
of the disease occurring may be somewhat unattractive to
patients without the prospect of an effective treatment. In
order to ascertain whether biomedical research will be
translated into health care practice, understanding and
predicting behaviour is of paramount importance. Trans-
lation of genetic knowledge about Paget's disease into
practice requires information on the following:
(i) Are people with Paget's disease willing to let their rela-
tives to know of their diagnosis?
(ii) Are people who are genetically related to people with
Paget's disease identifiable and happy to be contacted?
(iii) Are medical practitioners likely to refer relatives for
genetic testing?
(iv) Are these relatives likely to take a test?
(v) if such a test is positive, are medical practitioners likely
to prescribe preventive treatment? and
(vi) Are the relatives likely to adhere to such treatment?
This study concerns points (i), (ii), (iv) and (vi) in this
sequence.
Thus, this study aims to test the feasibility of translating
genetic knowledge into practice by examining the accept-
ability of offering genetic testing, followed by therapeutic
intervention, to relatives of people with a genetic disease.
The study will use established models of social cognition
within the field of behavioural science to achieve this.
This study will focus on Paget's disease of bone, for which
genetic mutations have been identified, and potential
effective treatments exist.
Paget's disease of bone
Paget's disease of bone (PDB) is a common disorder that
affects about 2% of individuals over the age of 55 in the
UK [1]. It is characterised by focal increases in osteoclastic
bone resorption, coupled to increased and disorganised
bone formation affecting one or more bones throughout
the skeleton. Some patients are asymptomatic, but others
develop complications such as bone pain, bone deform-
ity, pathological fracture, deafness and secondary osteoar-
thritis [1]. These complications cause loss of mobility and
independence, and adversely affect quality of life [2].
Genetic factors play an important role in PDB and in 15–
40% of families, the disease is inherited as an autosomal
dominant trait [3-5]. Mutations have now been identified
in four genes that predispose to PDB and related diseases
(reviewed by Daroszewska & Ralston [6]) but the most
important of these is SQSTM1 which is a common cause
of classical Paget's disease. About 40% of patients with a
familial PDB in the UK carry SQSTM1 mutations as do 9%
of patients with "sporadic" PDB [7,8]. The proportion of
SQSTM1 mutation carriers is higher in the French Cana-Page 2 of 13
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20% of "sporadic" patients have SQSTM1 mutations [9].
Individuals with SQSTM1 mutations are severely affected.
The age at diagnosis is about 10 years younger and the dis-
ease is more extensive than in PDB patients without
SQSTM1 mutations [7]. Twelve different mutations of
SQSTM1 have been described in patients with PDB and all
of these cluster in or around the ubiquitin associated
(UBA) domain [10].
Functional studies have shown that SQSTM1 mutations
cause loss of ubiquitin binding [10], suggesting that this
may be a unifying mechanism by which the disease
occurs, although research is still ongoing to determine
how this leads to osteoclast activation.
A few examples have been recorded where carriers of
SQSTM1 mutations have not developed PDB, even by the
seventh decade [9]. This has led to the suggestion that
environmental factors such as measles virus infection
might interact with SQSTM1 mutations to cause PDB
[11]. The contribution of viral infection to the pathogen-
esis of PDB remains controversial, however [12,13]. In
any case, irrespective of the possible contribution of envi-
ronmental factors, between 80%–90% of SQSTM1 carri-
ers develop PDB by the sixth or seventh decade [7,9,14].
Importantly, mutations of SQSTM1 are highly specific for
PDB and have not been found in unaffected age matched
controls derived from the general population in any of the
studies that have been performed so far [9,14-17].
Progress in understanding the role of SQSTM1 in the
pathogenesis of PDB has been accompanied by major
advances in treatment of the condition.
In view of this, it is timely to investigate the clinical poten-
tial for a programme of genetic testing and preventive
treatment for patients who carry SQSTM1 mutations, in
an effort to prevent or delay the development of Paget's
disease.
Prospects for preventing Paget's disease
Aminobisphosphonates such as Risedronate, Pamidro-
nate and Zoledronate have emerged as highly effective
agents for reducing bone turnover and treating bone pain
in patients with Paget's disease [18]. Recent studies have
shown that a single infusion of the fourth generation ami-
nobisphosphonate, Zoledronic acid, can restore alkaline
phosphatase levels to normal in about 90% of cases [19].
In the vast majority of these patients, alkaline phos-
phatase levels have remained normal for 24 months after
the infusion [20]. There is also evidence to suggest that
standard courses of treatment with intravenous Pamidro-
nate and oral Risedronate can suppress bone resorption in
active Paget's disease for up to two years [21,22].
This raises the possibility that patients who carry SQSTM1
mutations, and who are at high risk of developing Paget's
disease, could be offered prophylactic therapy, in an
attempt to prevent the disease occurring, or to prevent
complications developing. With the existence of effective
treatment that could prevent the onset of disease, we need
to explore the acceptability of genetic testing followed by
preventive treatment.
Acceptability of genetic testing and preventive treatment
In light of these developments in Paget's disease, it is
timely to investigate whether genetic testing and preven-
tive treatment are acceptable to the relatives of Paget's dis-
ease patients. 'Acceptability' has been conceptualised to
mean the following behaviours:
• whether relatives of people with Paget's disease would
accept such a test if it were offered;
• whether they would accept preventive treatment for
Paget's disease, if it were recommended by doctors; and
• if so, what type of treatment (e.g. tablet or injection)
they would be prepared to accept, if it were offered.
We have taken a theoretical approach to exploring accept-
ability by utilising the construct of intention toward the
key behaviours contained within recognised social cogni-
tion models [23]. Intention to engage in each of the above
three behaviours are our measures of acceptability. Within
social cognition models, intention is a strong predictor of
behaviour. While it is recognised that there is a gap
between intention and actual behaviour [24] i.e. intenders
do not always carry out the behaviour, it is very rare for
non-intenders to do so [25]. In addition, the gap between
other cognitions and behaviours is even greater [26]. For
example, attitudes to the tests and proposed treatments
i.e. the extent to which an individual is favourable toward
them, are likely to be less predictive of subsequent behav-
iours than intentions to engage in the behaviour of accept-
ing tests and treatment, as shown by Fishbein's seminal
work in the 1960s.
Possible factors that could affect acceptability of genetic 
testing and preventive treatment
Nevertheless, evidence from other areas of genetic testing
suggests that patients who say they wish to undertake
genetic testing may not actually take up the offer of such a
test.
In Huntington's disease, for example, prior to the devel-
opment of a genetic test, individuals at risk declared a
much higher intention of taking a test than the actual
numbers taking the test when it became available [27].
Although some people who stated having the intention toPage 3 of 13
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those people who did not hold this intention actually
took the test. Measuring intentions is, therefore, impor-
tant as it can very accurately identify those who will defi-
nitely not take a test.
Cognitions about genetic conditions in general can also
influence acceptability of genetic tests. For example, stud-
ies have shown that there is a widespread belief that
genetic conditions are not treatable. Such beliefs might
affect the acceptability of screening for and treatment of
genetic conditions. However, the additional offer of effec-
tive preventive treatment can make genetic testing more
acceptable [28]. It is, therefore, important to understand
the complex issues surrounding acceptability and uptake
prior to the development of new technologies to maxim-
ise the efficiency of health service provision.
Beliefs
Evidence from other, non-genetic, conditions, for which
there are effective treatments, demonstrates that patients'
cognitions may affect their intentions and therefore
uptake of treatment. Two groups of cognitions, represen-
tations about illness; and beliefs about behaviours that
constitute uptake of screening and treatment are likely to
be influential.
Illness representations
Illness representations describe how people see their ill-
ness. This is most clearly outlined in the Common Sense
Self-Regulation Model (CSSRM) [29]. The term 'self-regu-
lation' is defined here as 'processes of goal setting and goal
attainment' in response to a threat to health. The five key
beliefs that are the components of illness representations
are:
• identity (e.g. the 'label', identifying symptoms);
• cause (e.g. stress, genetics);
• consequences (e.g. activity limitations, loss of wages);
• timeline (e.g. acute, fluctuating, progressing);
• cure/control (e.g. medication, rehabilitation exercises,
prior perceived risk of developing the disease);
The model proposes that it is these perceptions, rather
than the medical representations, that guide the person's
self-regulating efforts. In addition, the CSSRM identifies
the emotional representation (e.g. frustrating, frightening) as
a separate dimension of representation. Based on this
model, Weinman and colleagues [30] have developed a
measure, the Illness Perceptions Questionnaire (IPQ), to
assess these representations and have found that they are
predictive of uptake and response to a wide variety of
treatments, including the bone disease Rheumatoid
Arthritis [31]. Clearly, such perceptions may influence
uptake of a new treatment offered to families with Paget's
disease. Indeed, Marteau has shown that beliefs affect the
decision to accept a genetic test [28].
Moss-Morris et al [32] have subsequently developed a
revised version of the Illness Perception Questionnaire
(IPQ-R) to include illness coherence (e.g. the condition is
understandable versus confusing). A brief version of the
IPQ-R has also been developed by Broadbent et al [33].
The Brief IPQ provides a rapid assessment of illness per-
ceptions that is quick and easy for participants to com-
plete.
Paget's disease has a highly variable presentation: age at
onset, severity of symptoms and impact on sufferers' lives;
and individuals might vary in their response to an offer of
testing and treatment depending on the disease history
within their family. Using the World Health Organisation
International Classification of Functioning, Disability and
Health model of health components [34], one might
expect that perceptions about all three components
(impairment, activity limitations, and participation
restrictions) might affect beliefs about the identity, conse-
quences and timeline of the condition.
Treatment representations
Treatment representations describe how people perceive
potential treatments for their disease. There is considera-
ble evidence that patients' beliefs about taking treatments
(e.g. ease of access, burden, perceived likelihood of suc-
cessful consequences) influence uptake and adherence
[35]. A programme of genetic testing and treatment
requires considerable behavioural input from the individ-
ual and their representations of what is involved rather
than the objective programme of treatment, are likely to
determine their willingness to participate.
Cognitions about the behaviours involved in uptake in 
uptake
The Theory of Planned Behaviour (TPB) is a theoretical
model (see Figure 1), which predicts intentions and
behaviour from people's beliefs about the consequences,
social pressures and perceived control over the behaviour,
including uptake of testing and uptake of treatment [36].
The TPB proposes that intention to perform a given
behaviour is shaped by a person's attitude, subjective
norms and perceived behavioural control relating to that
behaviour and gives clear guidance on how to operation-
alise these constructs.Page 4 of 13
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A person's attitude to a behaviour (i.e. whether they eval-
uative it positively or negatively) is shaped by their behav-
ioural beliefs (beliefs about the consequences of the
behaviour e.g. whether it will improve or prevent them
having Paget's disease), and their outcome evaluations
(the positive or negative features of the consequences of
the behaviour e.g. whether they consider avoiding Paget's
disease to be important).
Subjective Norms
A person's own perception of the beliefs and practices of
significant others (individuals or groups) as to whether
these significant others would approve or disapprove of
the behaviour, and the person's own motivation to com-
ply with these pressures. Subjective norms are shaped by
beliefs concerning how socially desirable or undesirable it
is to perform the behaviour e.g. whether they believe their
relatives would wish them to have genetic testing.
Perceived Behavioural Control
Beliefs about factors that make it easy or difficult for a per-
son to enact the behaviour combined with beliefs about
the power of those factors to enable them to enact the
behaviour. Control beliefs can be internal (e.g. informa-
tion, skills, abilities) or situational (e.g. opportunities,
barriers, dependence on others) e.g. whether the individ-
ual believes that genetic testing is possible for them.
Intention
Intention is the index of acceptability of genetic testing
and treatment for this study. It is the strength of motiva-
tion to enact the behaviour. The model describes how
people are more likely to engage in attractive behaviours
over which they have high levels of control. Behaviours
that carry high levels of intention and perceived behav-
ioural control should produce strong motivation to actu-
ally enact the behaviour. It is, therefore, possible to
produce a questionnaire based on the TPB model to pre-
dict intention to perform a given behaviour, such as
uptake of a genetic test or preventive treatment, i.e. accept-
ability.
The nature of the treatment and treatment offer
The nature of the treatment, and the way in which the
treatment is offered, may affect acceptability. One needs
to consider not only how to invite the affected individual
to 'involve' their family, but also how to introduce the
programme to invited family members. Hardeman et al
[37] in the Pro-Active Programme, have developed an
interview for families of people with Type 2 diabetes that
incorporates the offer of the intervention for offspring.
This interview was based on the data from interviews used
to develop questionnaires for the Theory of Planned
Behaviour (TPB) addressing beliefs about involving the
offspring in the programme. It has proved very effective in
rendering the programme acceptable.
In addition, the treatment offered for Paget's disease could
be in tablet or infusion form, and could be administered
in a range of environments. All of these factors may influ-
ence the acceptability of a programme of genetic testing
and preventive treatment and will be explored in this
study.
Demographic and health characteristics
Demographic and health-status characteristics may also
influence people's illness perceptions as well as their
beliefs about the behaviours involved and hence the
acceptability of treatment. For example, someone who is
older may think they are less at risk if they have passed the
age of onset of Paget's disease in the affected person; or
they may think they are nearing the time when the disease
might affect them; or they may think they are less likely to
benefit. Closeness to the affected person may make them
view the condition as more or less serious, and they may
be influenced by how the affected person copes with the
illness. Furthermore, one might expect there to be more
agreement within members of one family than between
families due to their shared exposure to the condition as
well as their opportunity to discuss and influence each
other (Figure 2).
We will therefore investigate how Paget's disease has
affected the proband, using the three health components
of the International Classification of Functioning [34] to
characterise the consequences of the disease, i.e. we will
assess impairment of body functioning and structure,
activity limitations and participation restrictions.
Scientific value of this study
This project takes advantage of recent advances in knowl-
edge about the molecular-genetic basis of PDB, with
Diagrammatic representation of the Theory of Planned BehaviourFigure 1
Diagrammatic representation of the Theory of 
Planned Behaviour.Page 5 of 13
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question that is of relevance to patients with Paget's dis-
ease and their families. The project provides added value
in that modern techniques and models in behavioural sci-
ence will be applied to a specific issue in the treatment of
Paget's disease, while at the same time investigating more
general theories of human behaviour. Using the Common
Sense Model of Self-Regulation, we will investigate how
genetic information and preventive opportunities affect
self-regulation via illness representations and, using the
Theory of Planned Behaviour, how the behaviour of
uptake of the offer of genetic testing and treatment is pre-
dicted by the constructs found to predict behaviour in
other settings. Thus, the findings will be relevant to these
theories. They will also contribute to ongoing work to
integrate these two models in understanding cognitions
and behaviour related to illness threats [38].
In addition, the knowledge gained from this investigation
would be relevant to other musculoskeletal diseases such
as osteoporosis, which also have a strong genetic compo-
nent, and which can be prevented by bisphosphonates
and hormone replacement therapy. With completion of
the human genome project, and advances in human
molecular genetics, it is probable that DNA testing with
single genetic markers or combinations of markers will be
offered for a wide range of other chronic diseases for
which effective treatments are available. The results of the
present research project will also be of direct relevance to
the development of programmes of genetic testing and
preventive intervention for these conditions.
Study Aim
The aims of this study are to understand factors that might
influence the acceptability of an offer of a programme of
genetic screening and preventive treatment to families of
Paget's disease sufferers.
The specific research questions are:
Stage 1. (already completed [39])
a): What do individuals with Paget's disease think would
influence the involvement of their relatives in a pro-
gramme of genetic testing and preventive treatment? and;
b) What do relatives of Paget's disease sufferers think
would influence them in accepting an offer of a pro-
gramme of genetic testing and preventive treatment?
Stage 2. (the focus of this protocol)
Do the following factors relate to acceptability of a pro-
gramme of genetic testing and preventive treatment in rel-
atives of people with Paget's disease:
• Illness and emotional representations of Paget's disease;
• Treatment representations;
• Presentation of the disease in affected relative(s) (age at
onset, impairment, activity limitations, participation
restrictions; family history as a function of the number of
affected relatives and the relationship to the Respondent);
• Respondent characteristics (age, gender and health);
• Cognitions about having a test and taking preventive
treatment;
• The nature of the treatment offered.
By answering these research questions, this study will cast
light on the feasibility of developing a programme of
genetic testing and preventive treatment for individuals
who are at high risk of developing Paget's disease because
they carry SQSTM1 mutations. We do not yet know
whether prophylactic bisphosphonate therapy would be
effective in preventing Paget's disease, however, we envis-
age that the results of the present study would be used to
inform the rationale of a randomised controlled trial to
investigate the efficacy of prophylactic bisphosphonate
therapy in people with SQSTM1 mutations. Such a study
would form the basis of a future research project.
Methods/Design
This research project has 2 stages.
A model of the relationship between explanatory and dependent variablesFigure 2
A model of the relationship between explanatory and 
dependent variables.Page 6 of 13
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This part of the study is completed and addressed the first
research question [39]. It aimed to identify factors that
would influence involvement of relatives not known to
have Paget's disease in a programme of genetic screening
and preventive treatment. Stage 1 employed semi-struc-
tured interviews developed to elicit CS-SRM constructs
and to form a basis for developing an Illness Perception
Questionnaire [32] for individuals suffering from Paget's
disease. It also employed Theory of Planned Behaviour
(TPB)-based interviews [40], with their relatives who had
not been diagnosed as suffering from Paget's disease to
elicit beliefs about the consequences of the behaviours of
accepting testing and treatment, about the views of impor-
tant others regarding these behaviours and about whether
these behaviours were easy or difficult for the respondent.
The results of Stage 1 have been used to inform the devel-
opment of this protocol and the questionnaire for Stage 2.
Stage 2
This part of the study is the focus of this protocol. The
Stage 2 has been reviewed and approved by Lothian
Research Ethics Committee 1 (ref: 07/S1101/13). It will
comprise a postal questionnaire study of people without
Paget's disease but who are relatives of people with Paget's
disease. This part of the study will address the second
research question.
Two sets of individuals will be identified:
(1) Relatives of Paget's patients with a family history of
Paget's disease (i.e. known history of Paget's disease in
more than one blood relative);
(2) Relatives of Paget's patients without a known family
history of Paget's disease (i.e. known history of Paget's dis-
ease in only one blood relative).
This stage aims to quantitatively assess the effect of a range
of factors on the acceptability of a programme of genetic
testing and preventive treatment in families with and
without a family history of Paget's disease. The question-
naire is likely to consist of several measures: illness repre-
sentations (as measured by the Brief Illness Perception
Questionnaire [33]); treatment representations (as meas-
ured by a TPB-based questionnaire informed by Stage 1
[39]); a series of dependent variables exploring the accept-
ability of testing and treatment and the feasibility of a
clinical trial of preventive treatment; questions collecting
descriptive and demographic details; and questions
exploring family environment and beliefs of other family
members.
Data will also be collected from probands to describe the
disease presentation and its distribution within a family.
The data from questionnaires completed by relatives will
be analysed along with available data on members of the
family with diagnosed Paget's disease (probands and
other affected family members).
Participants and recruitment
Individuals with Paget's disease will be identified, in the
first instance, from two established cohorts: The PRISM
trial and The Paget's Disease Family Register (PDFR).
Probands and relatives from the PDFR cohort, and
probands from the PRISM cohort, have previously given
their consent to future contact regarding Paget's disease
research (see Table 1 for additional details of how these
individuals were approached).
We can identify in total, 254 probands with a family his-
tory of Paget's disease, and 1020 individuals without a
family history of Paget's disease from these cohorts.
The PRISM Cohort
The PRISM cohort involves 1331 patients with Paget's dis-
ease from 39 collaborating centres ranging in size from 3
trial participants to approx 250 trial participants. Twenty
of these centres have agreed to allow us to approach their
patients for this study. We already know from the baseline
evaluation that approximately 172 individuals in PRISM
have a family history of Paget's disease, whereas 1020
individuals do not.
The Paget's Disease Family Register (PDFR)
We will also enrol participants with a family history of
Paget's disease from the PDFR. This register currently com-
prises 49 probands and their affected and unaffected rela-
tives from around the world. Families for this study have
been enrolled from the UK [16]. These participants have
already taken part in genetic mapping studies that resulted
Table 1: Approach to potential participants to invite them to participate in the GaP study
PRISM PDFR Edinburgh NARPD
Probands Approach directly (after 
consultation with caring physician)
Approach directly (after 
consultation with caring physician)
Approach directly (after 
consultation with caring physician)
Approach directly
Relatives Approach via proband Approach directly (after 
consultation with caring physician)
Approach via proband Approach via probandPage 7 of 13
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Paget's disease [3,8]. New families are being included on
an ongoing basis and these figures are subject to change.
Identifying and Contacting Participants
In the first instance, probands will be identified from both
the PRISM and PDFR cohorts. For the PRISM cohort, all
participants who have died, become unwell or who have
withdrawn from the PRISM study are recorded on the
PRISM database, and these participants will not be con-
tacted for this study. For the PDFR cohort, every attempt
will be made to avoid making inappropriate contact using
a variety of methods. For example, where possible the sta-
tus of probands will be checked with their caring physi-
cian/consultant.
If there is a high non-response from the PDFR and PRISM
cohorts, we will identify probands from additional
cohorts.
Contacting PRISM probands
Probands identified from the PRISM cohorts will be con-
tacted by post. A letter will be sent to all probands
together with a study information leaflet, inviting them to
complete a questionnaire. Probands will also be asked to
provide contact details of relatives over the age of 18 who
may also like to participate. PRISM probands have previ-
ously been asked if they are happy to be contacted about
new research projects, and only those agreeing to this will
be contacted.
Contacting relatives of PRISM probands
A letter will be sent to relatives identified by probands
together with a study information leaflet, inviting them to
complete a questionnaire.
Contacting probands and relatives from the PDFR cohort
A letter will be sent to probands and relatives identified
from the PDFR together with a study information leaflet,
inviting them to complete a questionnaire.
Questionnaire reminders
Non-response will be interpreted as a desire not to take
part in the study. If no response has been received by the
study office (Aberdeen) or Chief Investigator's office
(Edinburgh) to the initial mailing, participants will not
receive any subsequent questionnaire reminders or fur-
ther contact from the study office.
Sample Size
Given that most of these individuals have already engaged
in research, we anticipate a high participation rate and
estimate that 70% of probands will have living blood rel-
atives and will be happy to contact their relatives. Based
upon the experience of a recent study of familial hyperc-
holestorolaemia [41] it is anticipated that an average of 2
relatives per participating proband will participate. The
recommended minimum sample is calculated as 50 + 8
m, where m is the number of predictor variables [42]. This
study has a total number of 26 predictor variables and the
minimum sample size required is 258 relatives.
We anticipate that there will be a clustering effect of
responses within families. The size of clustering effect is
determined by the intra cluster correlation, and the sam-
ple size needs to be inflated to reflect this correlation [43].
We have no prior evidence of the possible size of this clus-
tering effect, so assuming that the study has an average
cluster size of 2 relatives per proband and that the correla-
tion was 1 (the worst case scenario), the inflation factor
would be 2. We therefore intend to recruit a minimum of
516 relatives to account for this effect. To achieve this it
will be necessary to approach a minimum of 369
probands (accounting for 70% participation rate). We
intend to approach a random sample of 200 probands
with a known family history of Paget's disease, and 200
without.
Exclusion criteria
Exclusion criteria include:
• Unable to read or write English; or
• Aged less than 18 years; or
• Known* limited life expectancy (under one year)
* The caveat of 'known' is used, as it may not be possible to
determine limited life expectancy of relatives.
We have not made special arrangements for non-English
speaking participants for two reasons:
• Paget's disease is extremely rare in non-Caucasians and
therefore we anticipate that English will be the first lan-
guage of virtually all, eligible individuals within the UK.
• The instruments used in this study (in particular the
BIPQ and TPB) are sophisticated and sensitive tools for
measuring an individual's perceptions of treatment and
illness. Translating these measures into alternative lan-
guages necessitates re-validation of these instruments,
which would require considerable investment of time and
financial resources that are not available for this study.
Individuals with limited life expectancy are excluded from
Stage 2 of the study as the process of completing a ques-
tionnaire may be cognitively and emotionally taxing for
them.Page 8 of 13
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years). Clinical studies suggest that people with SQSTM1
mutations develop Paget's disease from approximately 45
years of age onwards [7]. Clinical intuition would suggest
that starting a programme of preventive treatment at age
40 years would therefore be appropriate. The clinical evi-
dence to support this, however, is still lacking. In addi-
tion, it is likely that a psychologically 'acceptable' age for
beginning preventive treatment will differ from that indi-
cated by existing evidence. As such, we propose to include
all adult relatives of probands to determine the effect of
age of the acceptability of genetic testing, and preventive
treatment.
Consent Process
Although implied consent will be assumed if a subject
completes and returns a questionnaire, we have addition-
ally incorporated a brief consent form into the question-
naire to ensure that the following points are clearly
understood:
• The general purpose of the study and questionnaire are
understood;
• That the subject can withdraw from the study at any time
and if they specifically request it, their data will be
destroyed;
• The data is collected and securely stored by the Despatch
Office in Edinburgh;
• We are not able to offer a genetic test or preventive treat-
ment for Paget's disease as part of this study;
• That a summary of the results can be sent to them if they
indicate agreement.
It is explicitly stated in the consent forms and question-
naires that participants can withdraw from the study at
any time by contacting the study office and, if requested,
their data will be destroyed.
The consent form incorporated into the questionnaires
will also contain a tick box for participants to indicate
whether they wish contact about future research projects
concerning Paget's disease.
Measures
A questionnaire will be sent to probands. This question-
naire will include:
• Details of disease presentation in the proband;
• An overview of the family structure;
• Details of relatives to contact.
A questionnaire will be sent to first and second-degree rel-
atives of probands. This questionnaire will include spe-
cific measures of:
• All variables hypothesised to affect the likelihood of
uptake of a programme of genetic testing and preventive
treatment (potential explanatory variables; see section
6.1); and
• Dependent variables measuring the acceptability or
intention to take up an offer of a programme of genetic
testing and preventive treatment.
In addition, each section of the questionnaire will have a
section of open questions.
Potential explanatory variables
Illness and Emotional Representations
Illness and Emotional Representation will be assessed
using the Brief Illness Perception Questionnaire (BIPQ) [33])
adapted for Paget's disease of bone. This is a very widely
used predictive measure. Adaptations for specific condi-
tions are part of the standard use of the questionnaire and
Professor Weinman will provide critical feedback relating
to the adapted measure before use. Appropriateness of
items will also be tested for Discriminant Content Validity
[44].
Representations of Testing and Treatment Behaviours
Based on Stage 1 interviews, a questionnaire will be
designed to assess beliefs about the behaviours involved
in accepting a programme of genetic testing and preven-
tive treatment, using TPB constructs and methods. The
constructs are:
• attitudes to accepting a programme of genetic testing and
preventive treatment;
• subjective norm refers to beliefs that important others
would wish one to accept or not;
• perceived behavioural control refers to beliefs that a pro-
gramme of genetic testing and treatment will be offered
which they are able to accept; and
These constructs will be assessed using standard TPB
methods [40] and based on beliefs (behavioural, norma-
tive and control) elicited in Stage 1. All measures will con-
tain at least 3 items so that reliability can be assessed and
will be subjected to psychometric analyses.Page 9 of 13
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Age, gender, marital and employment status; relationship
with affected person(s), number of affected relatives; self-
assessed health as measured by SF-12 and self-assessed
health on standard 4-point rating scale (excellent, good,
fair, poor).
Presentation of the disease in affected relative(s)
The following data will be collected from the proband:
age at onset, previous fracture, previous bone surgery and
the number of bones affected by Paget's disease. In addi-
tion, the SF-36 will give standardised measures of impair-
ment, activity limitations, and participation restriction,
based on previous work on the relationship between this
measure and the ICF health components [45].
Dependent variable: Acceptability of a programme of 
genetic testing and preventive treatment
Acceptability will be assessed through: intention to accept
a test if offered and intention to accept preventive treat-
ment if recommended by doctors. In addition, relatives'
perceptions of the feasibility of taking preventive treat-
ment will be measured through perceived behavioural
control of particular forms of treatment. Intention and
perceived behavioural control will be assessed using
standard TPB methods [40].
Measures will be developed to assess probability of accept-
ance, using both numerical and verbal-rating scales and
guidance from work on presenting probabilistic risk data.
Using the TPB it is possible to measure intention and to
assess the probability of engaging in the described behav-
iour. Information from Stage 1 interviews will be used for
content, phrasing and context, and piloted in interviews
until satisfactory. Participants will be specifically asked
whether they would take up a programme of genetic test-
ing and preventive treatment if it were to become availa-
ble. In addition, we would specifically investigate the
acceptability of the following options: preventive treat-
ment options (tablet or infusion); and location of clinical
intervention for preventive treatment (primary or second-
ary care; regional specialist centres or local.
Data collection
Potential participants will be assigned a unique study
number. This information will be held on a password-
protected database/spreadsheet at the University of Edin-
burgh.
Questionnaires will be pre-labelled with these study num-
bers and posted to the corresponding potential partici-
pants. Questionnaires will be identifiable by the unique
study number only.
Probands and relatives will be asked to complete and
return the questionnaire in a reply-paid envelope. Help in
completing the questionnaire will be available if required.
If the patient is known to have difficulty writing (for
example due to severe arthritis), is deaf or blind, special
arrangements will be made for completion of the ques-
tionnaires.
Anne Langston, the Chief Investigator, and a data man-
ager based at the Queen's Medical Research Institute,
Edinburgh, will coordinate the administration of ques-
tionnaires and data management. Stage 2 will therefore be
administrated from this site, and will be Sponsored by the
University of Edinburgh.
Data will be returned by participants to the Edinburgh
Office. There it will be entered onto an electronic database
(password protected and stored on secure University
server). An experienced data clerk will enter the data from
questionnaires into this database. Anonymous data from
this database will be transferred to the GaP study office at
the University of Aberdeen for statistical analysis.
Quality Assurance
Full verification checks will be undertaken at the time of
data capture. A random 10% sample of data will be dou-
ble entered to check accuracy. Extensive range and consist-
ency checks will further enhance the quality of the data.
Analysis
Stage 2 data analyses will involve psychometric assess-
ment of developed and adapted measures. The main anal-
yses will be carried out by a statistician in collaboration
with Jill Francis, an expert in the psychometrics and anal-
ysis of theoretically based measures and analyses. and will
involve multiple and logistic regression; this will be
approached systematically, starting with analyses for each
theoretical approach and then for each group of variables
to identify significant predictors which will then be
brought into an overall predictive equation.
Answers to open ended questions will be analysed to clar-
ify content. The analysis of open questions will not
involve a full qualitative analysis of all responses, but
instead will be analysed as required to aid interpretation
of quantitative results. Members of the research team will
carry out this analysis. Detailed qualitative analysis may
be carried out in the future and will be subject to separate
funding and ethical approval.
End of Study procedures
During the consent process for the study we will ascertain
whether participants would like to be sent a report of the
study results.Page 10 of 13
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study results, a short report will be prepared and circu-
lated at the end of the study.
Questionnaires will be stored in locked filing cabinets
until the study is complete, and will then be anonymised
and archived for 20 years in accordance with Medical
Research Council guidelines. The Chief Investigator, Anne
Langston, will act as the Custodian of the data.
Confidentiality
The Chief Investigator Office, based in the Queen's Medi-
cal Research Institute, Edinburgh, is responsible for the
confidentiality of all study records. Potential participants
will be assigned a unique study number. This information
will be held on a password-protected database/spread-
sheet at Edinburgh University. Questionnaires will be pre-
labelled with these study numbers and posted to the cor-
responding potential participants. Questionnaires will be
identifiable by the unique study number only. In accord-
ance with Good Clinical Practice, and Institution codes of
conduct, all data will be password protected against unau-
thorised access and stored in accordance with the Data
Protection Act 1998. All stored data will be anonymised.
Finance and Indemnity
The study is supported by a grant from the Medical
Research Council (MRC). The University of Aberdeen
holds the grant. Sponsorship responsibilities will be
undertaken by the University of Edinburgh and NHS
Lothian.
Reporting and Dissemination
A summary of the results of the study will be prepared and
distributed, not only to the appropriate funding body, but
also to all participants (if they so wish). Results will be
published in peer-reviewed journals to make the results
available to both researchers on bone disease and
researchers on health-related behaviours.
Abbreviations
CSSRM: The Common Sense Self Regulation Model [29].
A psychological theory that aims to identify how people
perceive their illness. DNA: Deoxyribonucleic acid. The
substance that makes up genes. Familial Paget's disease:
Paget's disease that affects more than one member of a
family. ICF: International Classification of Function [34]
identifies three health components: impairment of body
structure and function; activity limitations; and participa-
tion restrictions. IPQ: The Illness Perceptions Question-
naire. This measures what people think about an illness in
themselves or others. IPQ-R: The Illness Perceptions
Questionnaire Revised [32]. This is a revised version of the
Illness Perceptions Questionnaire that includes a measure
of how understandable or confusing an illness is to peo-
ple. BIPQ: The Brief Illness Perceptions Questionnaire
[33]. This is a shortened version of the Illness Perceptions
Questionnaire Revised. MRC: Medical Research Council.
A UK government funded organisation that supports
medical research [46]. NARPD: National Association for
the Relief of Paget's Disease. A support group for people
with Paget's disease, their family and carers [47]. Non-
familial Paget's disease: Paget's disease that only affects
one person in a family. PDFR: Paget's Disease Family Reg-
ister. A study led by Prof Ralston, investigating the genet-
ics of Paget's disease. PRISM: A trial led by Prof Ralston
and co-ordinated by Dr Langston, investigating the treat-
ment of Paget's disease. Proband: Initial person of contact
within a family who has Paget's disease. Relative: A blood
relative of a proband (i.e. brother, sister, mother, father,
grandmother, grandfather, son, daughter, grandson,
grand daughter, nephew, niece). SF-36: A questionnaire
that measures general health, and quality of life. SF-12: A
shortened version of the SF-36 questionnaire. SQSTM1:
Sequestosome 1 [RNA NM_003900]. One of the genes
identified that, when 'faulty', causes Paget's disease. TPB:
The Theory of Planned Behaviour [40]. A psychological
theory that aims to identify predictors of behaviour using
a defined framework.
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